Fig 1: Examples of staining patterns in a hair follicle of normal human skin stained for SOX9 (a), CK19 (b), LRIG1 (c), and LGR5 (d)
Fig 2: Kaplan–Meier analysis of survival among patients whose tumors exhibited intermediate or strong (+ +), weak ( +), or negative (-) LRIG1 expression. a Overall survival. b Merkel cell carcinoma (MCC)-specific survival. Subject whose tumor exhibited LRIG1 expression had better overall survival (hazard ratio [HR] of death for weak expression = 0.72, 95% confidence interval [CI] = 0.42 to 1.24, and HR of death for intermediate or strong expression = 0.49, 95% CI = 0.28 to 0.88, P = 0.037) and MCC-specific survival (HR of death for weak expression = 0.43, 95% CI = 0.19 to 0.98, and HR of death for intermediate or strong expression = 0.42, 95% CI = 0.18 to 0.97, P = 0.021*) than those whose tumor lacked LRIG1 expression. Five- and 10-year survival data are shown. *Obtained by comparing cases exhibiting no LRIG1 expression to cases exhibiting any degree of positive LRIG1 expression
Fig 3: Examples of immunohistochemical staining results depicting dot-like and homogeneously positive CK19 expression (a and b), intermediate LGR5 expression (c), and strong LRIG1 expression (d), as well as heterogeneous and more homogeneous SOX9 expression (e and f)
Supplier Page from Abcam for Anti-LRIG1 antibody